Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
NCT ID: NCT04244825
Last Updated: 2021-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2019-12-15
2020-11-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
NCT03949530
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT03591926
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
NCT02846324
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
NCT04720443
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
NCT01766817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1a BLD-2660
900 mg (6 x 150 mg capsules) BID
BLD-2660
BLD-2660 - 150 mg capsules '00' size (PO) BID
Cohort 1b BLD-2660
900 mg (6 x 150 mg capsules) BID (Optional)
BLD-2660
BLD-2660 - 150 mg capsules '00' size (PO) BID
Cohort 2 BLD-2660
600 mg (4 x 150 mg capsules) BID
BLD-2660
BLD-2660 - 150 mg capsules '00' size (PO) BID
Cohort 3 BLD-2660
300 mg (2 x 150 mg capsules) BID
BLD-2660
BLD-2660 - 150 mg capsules '00' size (PO) BID
Cohort 1a Placebo
900 mg (6 x 150 mg capsules) BID
Control: Placebo
Placebo - 150 mg capsules '00' size (PO) BID
Cohort 1b Placebo
900 mg (6 x 150 mg capsules) BID (Optional)
Control: Placebo
Placebo - 150 mg capsules '00' size (PO) BID
Cohort 2 Placebo
600 mg (4 x 150 mg capsules) BID
Control: Placebo
Placebo - 150 mg capsules '00' size (PO) BID
Cohort 3 Placebo
300 mg (2 x 150 mg capsules) BID
Control: Placebo
Placebo - 150 mg capsules '00' size (PO) BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BLD-2660
BLD-2660 - 150 mg capsules '00' size (PO) BID
Control: Placebo
Placebo - 150 mg capsules '00' size (PO) BID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male subjects 45 years of age and over, or female subjects 50 years of age and over, at the time of signing the informed consent.
Diagnosis and disease characteristics
2. Subjects with diagnosis of IPF as defined by the American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonia.
3. Forced vital capacity (FVC) \>45% predicted and diffusing capacity of the lung for carbon monoxide (DLCO) \>30% predicted.
4. Alanine aminotransferase (ALT) within normal limit (WNL).
5. Aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤1.2× upper limit of normal (ULN).
6. Total bilirubin ≤ULN (isolated bilirubinemia ≤2× ULN is acceptable if direct bilirubin to total bilirubin ratio \<0.35).
7. Body mass index (BMI) up to 35 kg/m2 inclusive. Reproductive Considerations Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
8. All subjects (male or female) who are of childbearing potential must agree to use highly effective contraception during the study.
9. Male subjects and female partners of male subjects must continue to use highly effective contraception for 90 days after the last dose of study drug (see Medicines and Healthcare products Regulatory Agency, 2019 for further guidance regarding highly effective contraception). Male subjects must agree not to donate sperm for 90 days after last dose of study drug.
10. Female subjects and male partners of female subjects must continue to use highly effective contraception for 60 days after the last dose of study drug. Female subjects should not donate oocytes during this time.
11. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day (-1). Women of childbearing potential (WOCBP) must agree to undergo pregnancy testing at regular intervals throughout the study.
12. Female subjects not of childbearing potential as defined by being postmenopausal (with cessation of regular menstrual periods for at least 1 year), confirmed by follicle stimulating hormone (FSH) level, or be surgically sterile.
Informed Consent
13. Subjects must provide signed informed consent prior to study entry and have the ability and willingness to attend and comply with the necessary visits at the study site.
Exclusion Criteria
1. Recent (less than 6 weeks) significant wound (in the opinion of the Investigator), or presence of an ongoing non-healing skin wound or ulcer.
2. Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the subject will complete the study per protocol.
3. Active infection (diagnosed or suspected) or history of recurrent infections, including but is not limited to, bronchitis, pneumonia, sinusitis, urinary tract infection, cellulitis or chronic ongoing infectious disease within 4 weeks prior to first dose of study drug. Note: Rescreening will be permitted after 28 days if an infection leads to screening failure.
4. Active malignancy and/or history of malignancy in the past 5 years, except for non-melanoma skin cancer, carcinoma in situ of the breast that has been successfully treated, carcinoma in situ of the cervix that has been successfully treated, early stage, untreated prostate cancer, or prostate cancer with completion of treatment \>2 years prior to Screening.
5. Extensive chronic obstructive pulmonary disease (where extent of emphysema \>extent of fibrosis on computerised tomography (CT) scan or FEV1: FVC ratio \<0.65).
6. Other explanation for lung fibrosis, including but not limited to radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia, collagen vascular disease, hypersensitivity pneumonitis, etc.
7. IPF exacerbation within last 60 days.
8. A history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subjects' participation for the full duration of the study, or is not in the best interest of the subjects to participate, in the opinion of the Investigator.
Diagnostic Assessments
9. Positivity for Human Immunodeficiency Virus (HIV) antibody (HIV-1 and/or HIV-2) and/or HIV-1 p24 antigen.
10. Positivity for Hepatitis C virus antibody (HCV Ab or anti-HCV) and/or Hepatitis B surface antigen (HBsAg).
11. Absolute neutrophil count \<1700/µL.
12. Significant hypoxia, requiring \>2 L/min oxygen to maintain a resting oxygen saturation \>89%.
13. Poor exercise tolerance.
14. Serum troponin I level \>ULN.
Prior/Concomitant Therapy
15. Use of anticoagulants that prolong Prothrombin time (PT)/International normalised ratio (INR).
16. Use of anticoagulants within 2 days of Day (-1) (bronchoscopy). Note: The subjects who cannot discontinue the anticoagulants within 2 days of Day (-1) bronchoscopy will be excluded.
17. Treatment with any anti-fibrotic therapy (pirfenidone or nintedanib) within 30 days of Screening.
18. Immunosuppressive therapy within 3 months prior to first dose of study drug (unless for non-IPF indication).
19. Use of oral steroids \>10 mg/day (or prednisolone equivalent). Note: If the subject is on steroid dose equivalent to 10 mg/day prednisone or more, the Investigator may decide if the tapering down to the dose of 10 mg/day prednisone is possible and safe.
20. Start of new biologic or change in biologic dose within 24 weeks prior to Day 1.
21. Cyclophosphamide within 6 months prior to the first dose of study drug (unless for other indication).
Prior/Concurrent Clinical Study Experience
22. Administration of another investigational product, investigational device, or approved therapy for investigational use within 30 days prior to the first study drug administration, or five half-lives, whichever is longer.
Other Exclusions
23. Blood donation or significant blood loss within 60 days prior to the first study drug administration.
24. Plasma donation within 7 days prior to the first study drug administration.
25. Female subjects who are pregnant or breastfeeding.
26. History or presence of alcohol or drug abuse (including recreational marijuana use) within the 2 year prior to the first study drug administration, and unwillingness to be totally abstinent during the dosing period.
27. Active smoker, smoking history or vaping within 4 weeks prior to the first dose of study drug. Subjects only using Nicotine replacement therapy (NRT) may be allowed per discretion of the Investigator.
28. Subjects with an allergy to BLD-2660 or inactive components of BLD-2660.
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Blade Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Blade Research Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B-2660-203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.